Page last updated: 2024-11-05

mexacarbate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mexacarbate: insecticide & acaricide; minor descriptor (75-82); online & Index Medicus search INSECTICIDES, CARBAMATE (75-82) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9414
CHEMBL ID454804
CHEBI ID82092
SCHEMBL ID121459
MeSH IDM0262440

Synonyms (71)

Synonym
phenol, 4-(dimethylamino)-3,5-dimethyl-, methylcarbamate (ester)
mexacarbate
315-18-4
4-(dimethylamino)-3,5-dimethylphenyl methylcarbamate
carbamate, 4-dimethylamino-3,5-xylyl n-methyl-
einecs 206-249-3
nci-c00544
4-(dimethylamino)-3,5-xylyl methylcarbamate
methyl-4-dimethylamino-3,5-xylyl carbamate
4-(dimethylamine)-3,5-xylyl n-methylcarbamate
oms 639
caswell no. 579b
zectran
ai3-25766
4-(dimethylamino)-3,5-dimethylphenol methylcarbamate (ester)
carbamic acid, methyl-, 4-(dimethylamino)-3,5-dimethylphenyl ester
mexicarbate
methyl-4-dimethylamino-3,5-xylyl ester of carbamic acid
dowco 139
zectrane
hsdb 1042
methylcarbamic acid, 4-(dimethylamino)-3,5-xylyl ester
mexacarbate [ansi]
brn 2216978
4-(dimethylamino)-3,5-dimethylphenyl n-methylcarbamate
3,5-dimethyl-4-(dimethylamino)phenyl methylcarbamate
zectane
3,5-xylenol, 4-(dimethylamino)-, methylcarbamate
4-dimethylamino-3,5-xylyl n-methylcarbamate
4-dimethylamino-3,5-xylyl methylcarbamate
epa pesticide chemical code 044201
zextran
ent 25766
ccris 411
carbamic acid, methyl-, 4-(dimethylamino)-3,5-xylyl ester
4-dimethylamino-3,5-xylyl-n-methylcarbamate
oms-47
4-(n,n-dimethylamino)-3,5-xylyl n-methylcarbamate
4-(dimethylamino)-3,5-xylenol, methylcarbamate (ester)
carbamic acid, methyl-, 4-dimethylamino-3,5-xylyl ester
MAZ ,
[4-(dimethylamino)-3,5-dimethylphenyl] n-methylcarbamate
chebi:82092 ,
CHEMBL454804
NCGC00248781-01
C18952
dtxcid50893
cas-315-18-4
tox21_200649
dtxsid7020893 ,
NCGC00258203-01
mexacarbate [ansi:iso]
unii-ztm4ipv8g8
ztm4ipv8g8 ,
mexacarbate [mi]
mexacarbate [iso]
zectran [iarc]
phenol, 4-(dimethylamino)-3,5-dimethyl-, 1-(n-methylcarbamate)
methylcarbamic acid 4-(dimethylamino)-3,5-xylyl ester
mexacarbate [hsdb]
SCHEMBL121459
4-(dimethylamino)-3,5-xylenol, methylcarbamate
4-(dimethylamino)-3,5-dimethylphenyl methylcarbamate #
ent 25,766
phenol, 4-(dimethylamino)-3,5-dimethyl-, methylcarbamate
4-(dimethylamino)-3,5-dimethylphenol methylcarbamate
4-dimethylamino-3,5-dimethylphenyl n-methylcarbamate
carbamic acid, 3,5-dimethyl-4-dimethylaminophenyl ester, n-methyl
mexacarbate, pestanal(r), analytical standard
pesticide9_mexacarbate_c12h18n2o2_4-(dimethylamino)-3,5-dimethylphenyl methylcarbamate
Q6825702

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Zectran (4-dimethylamino-3,5-xylyl N-methyl-carbamate), a carbamate insecticide (active ingredient [AI] mexacarbate), was aerially applied to two 300 ha plots of coniferous forest at dosage rates of 70 and 140 g AI/ha, respectively."( An interlaboratory comparison of data on brain cholinesterase activity in forest songbirds exposed to aerial application of Zectran.
Busby, DG; Fleming, RA; Holmes, SB, 1992
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency4.54910.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
GLI family zinc finger 3Homo sapiens (human)Potency27.87220.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency57.18510.000221.22318,912.5098AID1259381; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency34.37620.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency18.48760.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.45170.000817.505159.3239AID1159527; AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency30.63790.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.49810.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency68.58960.000723.06741,258.9301AID743085; AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency60.01230.001628.015177.1139AID1224843; AID1224895
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency64.75280.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID399286In vivo inhibition of acetylcholinesterase from nerve tissue of Lymnaea acuminata at 2.5 mg/L relative to control
AID399292Inhibition of acetylcholinesterase from nerve tissue of Lymnaea acuminata at 1 ug w/v relative to control
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.86 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]